Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review

키워드

참고문헌 (61)

1. Davies J, "Procalcitonin", J Clin Pathol, 68, pp.675~679 (2015)
2. Michael Meisner, "Update on Procalcitonin Measurements", Annals of Laboratory Medicine, 34(4), pp.263~273 (2014), 대한진단검사의학회
3. Assicot M, "High serum procalcitonin concentrations in patients with sepsis and infection", Lancet, 341, pp.515~518 (1993)
4. Maruna P, "Physiology and genetics of procalcitonin", Physiol Res, 49(Suppl 1), pp.S57~S61 (2000)
5. Dandona P, "Procalcitonin increase after endotoxin injection in normal subjects", J Clin Endocrinol Metab, 79, pp.1605~1608 (1994)
6. Vijayan AL, "Procalcitonin : a promising diagnostic marker for sepsis and antibiotic therapy", J Intensive Care, 5, pp.51~ (2017)
7. Becker KL, "Clinical review 167 : Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis : a journey from calcitonin back to its precursors", J Clin Endocrinol Metab, 89, pp.1512~1525 (2004)
8. Aloisio E, "Procalcitonin : Between evidence and critical issues", Clin Chim Acta, 496, pp.7~12 (2019)
9. Nargis W, "Procalcitonin versus C-reactive protein : Usefulness as biomarker of sepsis in ICU patient", Int J Crit Illn Inj Sci, 4, pp.195~199 (2014)
10. Markanday A, "Acute phase reactants in infections : Evidence-based review and a guide for clinicians", Open Forum Infect Dis, 2, pp.ofv098~ (2015)
11. Harbarth S, "Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis", Am J Respir Crit Care Med, 164, pp.396~402 (2001)
12. Krüger S, "Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes", Eur Respir J, 31, pp.349~355 (2008)
13. Giamarellos-Bourboulis EJ, "Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia", Clin Infect Dis, 32, pp.1718~1725 (2001)
14. von Lilienfeld-Toal M, "Markers of bacteremia in febrile neutropenic patients with hematological malignancies : procalcitonin and IL-6 are more reliable than C-reactive protein", Eur J Clin Microbiol Infect Dis, 23, pp.539~544 (2004)
15. Tokman S, "Procalcitonin predicts mortality in HIV-infected Ugandan adults with lower respiratory tract infections", Respirology, 19, pp.382~388 (2014)
16. Yu XY, "Diagnostic value of serum procalcitonin in solid organ transplant recipients : a systematic review and meta-analysis", Transplant Proc, 46, pp.26~32 (2014)
17. Li S, "Procalcitonin and C-reactive protein predict infection in hematopoietic stem cell transplantation patients", Leuk Res, 105, pp.106574~ (2021)
18. Annborn M, "Procalcitonin after cardiac arrest-an indicator of severity of illness, ischemia-reperfusion injury and outcome", Resuscitation, 84, pp.782~787 (2013)
19. Mimoz O, "Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome", Intensive Care Med, 24, pp.185~188 (1998)
20. Meisner M, "Postoperative plasma concentrations of procalcitonin after different types of surgery", Intensive Care Med, 24, pp.680~684 (1998)
21. Carsin H, "Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury", Burns, 23, pp.218~224 (1997)
22. Kylänpää-Bäck ML, "Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis", Crit Care Med, 29, pp.63~69 (2001)
23. Muroi C, "Early systemic procalcitonin levels in patients with aneurysmal subarachnoid hemorrhage", Neurocrit Care, 21, pp.73~77 (2014)
24. Dong R, "Procalcitonin and liver disease : A literature review", J Clin Transl Hepatol, 7, pp.51~55 (2019)
25. Karagiannis AK, "Procalcitonin: A new biomarker for medullary thyroid cancer? a systematic review", Anticancer Res, 36, pp.3803~3810 (2016)
26. Yoshikawa H, "Serum procalcitonin value is useful for predicting severity of Kawasaki disease", Pediatr Infect Dis J, 31, pp.523~525 (2012)
27. Grace E, "Use of procalcitonin in patients with various degrees of chronic kidney disease including renal replacement therapy", Clin Infect Dis, 59, pp.1761~1767 (2014)
28. Dornbusch HJ, "Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders", Support Care Cancer, 16, pp.1035~1040 (2008)
29. Christensen AM, "Are procalcitonin or other infection markers useful in the detection of group A streptococcal acute tonsillitis?", Scand J Infect Dis, 46, pp.376~383 (2014)
30. Pallin DJ, "Toward an objective diagnostic Test for Bacterial Cellulitis", PLoS One, 11, pp.e0162947~ (2016)
31. Christ-Crain M, "Procalcitonin in bacterial infections--hype, hope, more or less?", Swiss Med Wkly, 135, pp.451~460 (2005)
32. Haeuptle J, "Prognostic value of procalcitonin in Legionella pneumonia", Eur J Clin Microbiol Infect Dis, 28, pp.55~60 (2009)
33. Stockmann C, "Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia", J Pediatric Infect Dis Soc, 7, pp.46~53 (2018)
34. Roques M, "Evolution of procalcitonin, C-reactive protein and fibrinogen levels in neutropenic leukaemia patients with invasive pulmonary aspergillosis or mucormycosis", Mycoses, 59, pp.383~390 (2016)
35. Charles PE, "Serum procalcitonin levels in critically ill patients colonized with Candida spp : new clues for the early recognition of invasive candidiasis?", Intensive Care Med, 35, pp.2146~2150 (2009)
36. Uzzan B, "Serum procalcitonin in uncomplicated falciparum malaria : a preliminary study", Travel Med Infect Dis, 4, pp.77~80 (2006)
37. Nyamande K, "Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP", Int J Tuberc Lung Dis, 10, pp.510~515 (2006)
38. Schuetz P, "Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections : the ProHOSP randomized controlled trial", JAMA, 302, pp.1059~1066 (2009)
39. Schuetz P, "Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections", Cochrane Database Syst Rev, 10, pp.CD007498~ (2017)
40. "FDA clears test to help manage antibiotic treatment for lower respiratory tract infections and sepsis"[URL]
41. Huang DT, "Procalcitonin-guided use of antibiotics for lower respiratory tract infection", N Engl J Med, 379, pp.236~249 (2018)
42. Metlay JP, "Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America", Am J Respir Crit Care Med, 200, pp.e45~e67 (2019)
43. Torres A, "International ERS", ESICM, ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia : Guidelines for the management of hospital-acquired pneumonia(HAP), pp.ventilator-associated pneumonia(VAP)of the European Respiratory Society(ERS), European Society of Intensive Care Medicine(ESICM), European Society of Clinical Microbiology and Infectious Diseases(ESCMID)and Asociación Latinoamericana del Tórax(ALAT), Eur Respir J[DOI]
44. Kalil AC, "Executive summary : Management of adults with hospital-acquired and ventilator-associated pneumonia : 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clin Infect Dis, 63, pp.575~582 (2016)
45. "Notification of the Ministry of Health and Welfare 2022-34"[URL]
46. 김종훈, "Korean Registry for Improving Sepsis Survival (KISS): Protocol for a Multicenter Cohort of Adult Patients with Sepsis or Septic Shock", Infection and Chemotherapy, 52(1), pp.31~38 (2020), 대한감염학회[DOI]
47. Hyeri Seok, "Antimicrobial Therapy and Antimicrobial Stewardship in Sepsis", Infection and Chemotherapy, 52(1), pp.19~30 (2020), 대한감염학회[DOI]
48. Bouadma L, "Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units(PRORATA trial) : a multicentre randomised controlled trial", Lancet, 375, pp.463~474 (2010)
49. de Jong E, "Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients : a randomised, controlled, open-label trial", Lancet Infect Dis, 16, pp.819~827 (2016)
50. Wirz Y, "Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients : a patient-level meta-analysis of randomized trials", Crit Care, 22, pp.191~ (2018)
51. "Notification of the Ministry of Health and Welfare 2015-123"[URL]
52. Evans L, "Surviving sepsis campaign : International guidelines for management of sepsis and septic shock 2021", Crit Care Med, 49, pp.e1063~e1143 (2021)
53. Tamma PD, "Molecular epidemiology of ceftriaxone non-susceptible Enterobacterales isolates in an academic medical center in the United States", Open Forum Infect Dis, 6, pp.ofz353~ (2019)
54. Langford BJ, "A real-world assessment of procalcitonin combined with antimicrobial stewardship in a community ICU", J Crit Care, 57, pp.130~133 (2020)
55. Collins CD, "Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis", Am J Health Syst Pharm, 76, pp.1219~1225 (2019)
56. Kwak Mi Young, "Development and Roll-Out of A Coronavirus Disease 2019 Clinical Pathway for Standardized Qualified Care in Public Hospitals in Korea", Infection and Chemotherapy, 54(2), pp.353~359 (2022), 대한감염학회[DOI]
57. Galang – De Leon Waiva Ann M., "Prevalence of Empiric Antibacterial Therapy, Community-Acquired Bacterial Superinfection, and Antibiotic-Associated Adverse Reactions among Patients with COVID-19 Pneumonia Admitted in Makati Medical Center from March 2020 to March 2021", Infection and Chemotherapy, 54(2), pp.266~274 (2022), 대한감염학회[DOI]
58. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
59. van Berkel M, "Biomarkers for antimicrobial stewardship : a reappraisal in COVID-19 times?", Crit Care, 24, pp.600~ (2020)
60. Williams EJ, "Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection : a retrospective cohort study", J Hosp Infect, 110, pp.103~107 (2021)
61. Kyriazopoulou E, "Procalcitonin to reduce long-term infectionassociated adverse events in sepsis. A randomized trial", Am J Respir Crit Care Med, 203, pp.202~210 (2021)